nerve Search Results


90
Cusabio elisa kit
Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve/Rat+Nerve+growth+factor%2CNGF+ELISA+kit/10__1007_slash_s43994___022___00001___w-89-0-2
Average 90 stars, based on 1 article reviews
elisa kit - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Rockland Immunochemicals anti vgf
Anti Vgf, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve/VGF+Antibody/pmc09138053-42-7-4
Average 93 stars, based on 1 article reviews
anti vgf - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Alomone Labs trka
Trka, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve/Anti-TrkA+(extracellular)+Antibody/pmc09321700-6-0-2
Average 94 stars, based on 1 article reviews
trka - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Alomone Labs anti prongf
Figure 4. Biological effect of targeting proNGF in GBM cells. GBM cell growth was studied in a panel of GBM cell lines with methylated MGMT gene promoter (A) and unmethylated MGMT gene promoter (B) as well as human astrocytes (HA, served as a control cell line) treated with blocking antibodies against proNGF <t>(anti-proNGF,</t> 600 ng/mL), TMZ (50 µM) and anti-proNGF + TMZ for 72 h. Data shown are the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Student’s t-test or ANOVA. proNGF: precursor for nerve growth factor, TMZ: Temozolomide. Black bars: PBS (vehicle control for anti-proNGF) + DMSO (vehicle control for TMZ); blue bars: anti-proNGF + DMSO (vehicle control for TMZ); purple bars: TMZ + PBS (vehicle control for anti-proNGF); orange bars: anti-proNGF + TMZ.
Anti Prongf, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve/Anti-proNGF+Antibody/pm36675126-222-4-10
Average 93 stars, based on 1 article reviews
anti prongf - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Alomone Labs rabbit anti ngf neutralizing antibodies
Figure 4. Biological effect of targeting proNGF in GBM cells. GBM cell growth was studied in a panel of GBM cell lines with methylated MGMT gene promoter (A) and unmethylated MGMT gene promoter (B) as well as human astrocytes (HA, served as a control cell line) treated with blocking antibodies against proNGF <t>(anti-proNGF,</t> 600 ng/mL), TMZ (50 µM) and anti-proNGF + TMZ for 72 h. Data shown are the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Student’s t-test or ANOVA. proNGF: precursor for nerve growth factor, TMZ: Temozolomide. Black bars: PBS (vehicle control for anti-proNGF) + DMSO (vehicle control for TMZ); blue bars: anti-proNGF + DMSO (vehicle control for TMZ); purple bars: TMZ + PBS (vehicle control for anti-proNGF); orange bars: anti-proNGF + TMZ.
Rabbit Anti Ngf Neutralizing Antibodies, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve/Anti-NGF+Antibody/pm23562155-169-16-20
Average 94 stars, based on 1 article reviews
rabbit anti ngf neutralizing antibodies - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Alomone Labs ngf
Figure 4. Biological effect of targeting proNGF in GBM cells. GBM cell growth was studied in a panel of GBM cell lines with methylated MGMT gene promoter (A) and unmethylated MGMT gene promoter (B) as well as human astrocytes (HA, served as a control cell line) treated with blocking antibodies against proNGF <t>(anti-proNGF,</t> 600 ng/mL), TMZ (50 µM) and anti-proNGF + TMZ for 72 h. Data shown are the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Student’s t-test or ANOVA. proNGF: precursor for nerve growth factor, TMZ: Temozolomide. Black bars: PBS (vehicle control for anti-proNGF) + DMSO (vehicle control for TMZ); blue bars: anti-proNGF + DMSO (vehicle control for TMZ); purple bars: TMZ + PBS (vehicle control for anti-proNGF); orange bars: anti-proNGF + TMZ.
Ngf, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve/Recombinant+human+beta-NGF+protein/pmc04319045-44-5-7
Average 93 stars, based on 1 article reviews
ngf - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

95
Alomone Labs ngf 2 5
Figure 4. Biological effect of targeting proNGF in GBM cells. GBM cell growth was studied in a panel of GBM cell lines with methylated MGMT gene promoter (A) and unmethylated MGMT gene promoter (B) as well as human astrocytes (HA, served as a control cell line) treated with blocking antibodies against proNGF <t>(anti-proNGF,</t> 600 ng/mL), TMZ (50 µM) and anti-proNGF + TMZ for 72 h. Data shown are the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Student’s t-test or ANOVA. proNGF: precursor for nerve growth factor, TMZ: Temozolomide. Black bars: PBS (vehicle control for anti-proNGF) + DMSO (vehicle control for TMZ); blue bars: anti-proNGF + DMSO (vehicle control for TMZ); purple bars: TMZ + PBS (vehicle control for anti-proNGF); orange bars: anti-proNGF + TMZ.
Ngf 2 5, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve/Native+mouse+NGF+2%2E5S+protein/pmc12355597-37-6-8
Average 95 stars, based on 1 article reviews
ngf 2 5 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
Alomone Labs glial cell derived neurotrophic factor
Figure 4. Biological effect of targeting proNGF in GBM cells. GBM cell growth was studied in a panel of GBM cell lines with methylated MGMT gene promoter (A) and unmethylated MGMT gene promoter (B) as well as human astrocytes (HA, served as a control cell line) treated with blocking antibodies against proNGF <t>(anti-proNGF,</t> 600 ng/mL), TMZ (50 µM) and anti-proNGF + TMZ for 72 h. Data shown are the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Student’s t-test or ANOVA. proNGF: precursor for nerve growth factor, TMZ: Temozolomide. Black bars: PBS (vehicle control for anti-proNGF) + DMSO (vehicle control for TMZ); blue bars: anti-proNGF + DMSO (vehicle control for TMZ); purple bars: TMZ + PBS (vehicle control for anti-proNGF); orange bars: anti-proNGF + TMZ.
Glial Cell Derived Neurotrophic Factor, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve/Recombinant+human+Neurotrophin-3+(NT-3)+protein/pm34326453-162-35-40
Average 95 stars, based on 1 article reviews
glial cell derived neurotrophic factor - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
Alomone Labs nerve growth factor 7s
Figure 4. Biological effect of targeting proNGF in GBM cells. GBM cell growth was studied in a panel of GBM cell lines with methylated MGMT gene promoter (A) and unmethylated MGMT gene promoter (B) as well as human astrocytes (HA, served as a control cell line) treated with blocking antibodies against proNGF <t>(anti-proNGF,</t> 600 ng/mL), TMZ (50 µM) and anti-proNGF + TMZ for 72 h. Data shown are the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Student’s t-test or ANOVA. proNGF: precursor for nerve growth factor, TMZ: Temozolomide. Black bars: PBS (vehicle control for anti-proNGF) + DMSO (vehicle control for TMZ); blue bars: anti-proNGF + DMSO (vehicle control for TMZ); purple bars: TMZ + PBS (vehicle control for anti-proNGF); orange bars: anti-proNGF + TMZ.
Nerve Growth Factor 7s, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve/Native+mouse+NGF+7S+protein/pmc04254330-330-39-43
Average 95 stars, based on 1 article reviews
nerve growth factor 7s - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

93
Alomone Labs mouse ngf biotin
Figure 4. Biological effect of targeting proNGF in GBM cells. GBM cell growth was studied in a panel of GBM cell lines with methylated MGMT gene promoter (A) and unmethylated MGMT gene promoter (B) as well as human astrocytes (HA, served as a control cell line) treated with blocking antibodies against proNGF <t>(anti-proNGF,</t> 600 ng/mL), TMZ (50 µM) and anti-proNGF + TMZ for 72 h. Data shown are the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Student’s t-test or ANOVA. proNGF: precursor for nerve growth factor, TMZ: Temozolomide. Black bars: PBS (vehicle control for anti-proNGF) + DMSO (vehicle control for TMZ); blue bars: anti-proNGF + DMSO (vehicle control for TMZ); purple bars: TMZ + PBS (vehicle control for anti-proNGF); orange bars: anti-proNGF + TMZ.
Mouse Ngf Biotin, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve/mouse+NGF+2%2E5S-Biotin/pmc09680784-108-12-15
Average 93 stars, based on 1 article reviews
mouse ngf biotin - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Alomone Labs rabbit anti nt3
Data: mean ± SD. ( A , B ) Intraperitoneal injection of paclitaxel produced mechanical allodynia as evidenced by the increases in paw withdrawal frequencies in response to 0.07 g ( A ) and 0.4 g ( B ) von Frey filaments on the left side. n = 12 mice/time point. * P < 0.05, ** P < 0.01 versus the vehicle-treated group at the corresponding time points by two-way ANOVA with repeated measures followed by post hoc Tukey test. ( C , D ) The levels of <t>Nt3</t> mRNA ( C ) and NT3 protein ( D ) in L3/4 DRGs on different days as indicated after the first injection of paclitaxel or vehicle. D: representative Western blots (left) and a summary of the densitometric analysis (right) are shown. n = 3 biological repeats (3 mice)/time point. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( E ) The amount of NT3 protein in the L3/4 spinal cord on different days as indicated after the first injection of paclitaxel. n = 3 biological repeated (3 mice)/time point. P > 0.05 by one-way ANOVA followed by post hoc Tukey test. .
Rabbit Anti Nt3, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nerve/Anti-Neurotrophin+3+(NT-3)+Antibody/pmc11094060-308-4-7
Average 94 stars, based on 1 article reviews
rabbit anti nt3 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


Figure 4. Biological effect of targeting proNGF in GBM cells. GBM cell growth was studied in a panel of GBM cell lines with methylated MGMT gene promoter (A) and unmethylated MGMT gene promoter (B) as well as human astrocytes (HA, served as a control cell line) treated with blocking antibodies against proNGF (anti-proNGF, 600 ng/mL), TMZ (50 µM) and anti-proNGF + TMZ for 72 h. Data shown are the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Student’s t-test or ANOVA. proNGF: precursor for nerve growth factor, TMZ: Temozolomide. Black bars: PBS (vehicle control for anti-proNGF) + DMSO (vehicle control for TMZ); blue bars: anti-proNGF + DMSO (vehicle control for TMZ); purple bars: TMZ + PBS (vehicle control for anti-proNGF); orange bars: anti-proNGF + TMZ.

Journal: International journal of molecular sciences

Article Title: ProNGF Expression and Targeting in Glioblastoma Multiforme.

doi: 10.3390/ijms24021616

Figure Lengend Snippet: Figure 4. Biological effect of targeting proNGF in GBM cells. GBM cell growth was studied in a panel of GBM cell lines with methylated MGMT gene promoter (A) and unmethylated MGMT gene promoter (B) as well as human astrocytes (HA, served as a control cell line) treated with blocking antibodies against proNGF (anti-proNGF, 600 ng/mL), TMZ (50 µM) and anti-proNGF + TMZ for 72 h. Data shown are the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Student’s t-test or ANOVA. proNGF: precursor for nerve growth factor, TMZ: Temozolomide. Black bars: PBS (vehicle control for anti-proNGF) + DMSO (vehicle control for TMZ); blue bars: anti-proNGF + DMSO (vehicle control for TMZ); purple bars: TMZ + PBS (vehicle control for anti-proNGF); orange bars: anti-proNGF + TMZ.

Article Snippet: Sections were labelled for anti-proNGF (0.8 μg/mL, catalogue number ANT005, Alomone labs, Jerusalem, Israel).

Techniques: Methylation, Control, Blocking Assay

Figure 5. In vivo targeting of proNGF in a mouse model of GBM. A xenograft mouse model of GBM was used. The human U87MG cells were injected subcutaneously between the shoulder blades of BALB/c nude mice, along with blocking anti-proNGF antibody (12 µg, intratumoral injection, twice a week for 4 weeks) and/or TMZ (50 mg/kg body weight, IP daily for 5 days) treatment for a 4-week course. (A) Representative photographs of U87MG tumors excised from mice after 4 weeks of treatment. Scale bar, 5 mm. (B) The growth curves of U87MG tumors in BALB/c nude mice (n = 9 for each group). (C) Comparison of volume of U87MG tumors harvested from mice treated with blocking anti-proNGF antibody and/or TMZ for 4 weeks. (D) Kaplan-Meier survival curves of BALB/c nude mice treated with anti-proNGF antibody and/or TMZ. Vehicle control vs. anti-proNGF: p = 0.0639; Vehicle control vs. TMZ: p < 0.0001; Vehicle control vs. anti-proNGF + TMZ: p = 0.0003; Anti-proNGF vs. anti-proNGF + TMZ: p = 0.0160, TMZ vs. anti-proNGF + TMZ: p = 0.8515. Data shown are the mean ± SD of tumors with 9 mice per treatment group. ProNGF: precursor for nerve growth factor, TMZ: Temozolomide. Vehicle control: PBS (vehicle control for anti-proNGF) + 5%GMSO + 30% Polyethylene glycol 300 (PEG300) + double-distilled H2O (vehicle control for TMZ); anti-proNGF: anti-proNGF + 5%GMSO + 30% PEG300 + double-distilled H2O (vehicle control for TMZ); TMZ: TMZ + PBS (vehicle control for anti-proNGF); anti-proNGF + TMZ: anti-proNGF + TMZ.

Journal: International journal of molecular sciences

Article Title: ProNGF Expression and Targeting in Glioblastoma Multiforme.

doi: 10.3390/ijms24021616

Figure Lengend Snippet: Figure 5. In vivo targeting of proNGF in a mouse model of GBM. A xenograft mouse model of GBM was used. The human U87MG cells were injected subcutaneously between the shoulder blades of BALB/c nude mice, along with blocking anti-proNGF antibody (12 µg, intratumoral injection, twice a week for 4 weeks) and/or TMZ (50 mg/kg body weight, IP daily for 5 days) treatment for a 4-week course. (A) Representative photographs of U87MG tumors excised from mice after 4 weeks of treatment. Scale bar, 5 mm. (B) The growth curves of U87MG tumors in BALB/c nude mice (n = 9 for each group). (C) Comparison of volume of U87MG tumors harvested from mice treated with blocking anti-proNGF antibody and/or TMZ for 4 weeks. (D) Kaplan-Meier survival curves of BALB/c nude mice treated with anti-proNGF antibody and/or TMZ. Vehicle control vs. anti-proNGF: p = 0.0639; Vehicle control vs. TMZ: p < 0.0001; Vehicle control vs. anti-proNGF + TMZ: p = 0.0003; Anti-proNGF vs. anti-proNGF + TMZ: p = 0.0160, TMZ vs. anti-proNGF + TMZ: p = 0.8515. Data shown are the mean ± SD of tumors with 9 mice per treatment group. ProNGF: precursor for nerve growth factor, TMZ: Temozolomide. Vehicle control: PBS (vehicle control for anti-proNGF) + 5%GMSO + 30% Polyethylene glycol 300 (PEG300) + double-distilled H2O (vehicle control for TMZ); anti-proNGF: anti-proNGF + 5%GMSO + 30% PEG300 + double-distilled H2O (vehicle control for TMZ); TMZ: TMZ + PBS (vehicle control for anti-proNGF); anti-proNGF + TMZ: anti-proNGF + TMZ.

Article Snippet: Sections were labelled for anti-proNGF (0.8 μg/mL, catalogue number ANT005, Alomone labs, Jerusalem, Israel).

Techniques: In Vivo, Xenograft Assay, Injection, Blocking Assay, Comparison, Control

Data: mean ± SD. ( A , B ) Intraperitoneal injection of paclitaxel produced mechanical allodynia as evidenced by the increases in paw withdrawal frequencies in response to 0.07 g ( A ) and 0.4 g ( B ) von Frey filaments on the left side. n = 12 mice/time point. * P < 0.05, ** P < 0.01 versus the vehicle-treated group at the corresponding time points by two-way ANOVA with repeated measures followed by post hoc Tukey test. ( C , D ) The levels of Nt3 mRNA ( C ) and NT3 protein ( D ) in L3/4 DRGs on different days as indicated after the first injection of paclitaxel or vehicle. D: representative Western blots (left) and a summary of the densitometric analysis (right) are shown. n = 3 biological repeats (3 mice)/time point. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( E ) The amount of NT3 protein in the L3/4 spinal cord on different days as indicated after the first injection of paclitaxel. n = 3 biological repeated (3 mice)/time point. P > 0.05 by one-way ANOVA followed by post hoc Tukey test. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. ( A , B ) Intraperitoneal injection of paclitaxel produced mechanical allodynia as evidenced by the increases in paw withdrawal frequencies in response to 0.07 g ( A ) and 0.4 g ( B ) von Frey filaments on the left side. n = 12 mice/time point. * P < 0.05, ** P < 0.01 versus the vehicle-treated group at the corresponding time points by two-way ANOVA with repeated measures followed by post hoc Tukey test. ( C , D ) The levels of Nt3 mRNA ( C ) and NT3 protein ( D ) in L3/4 DRGs on different days as indicated after the first injection of paclitaxel or vehicle. D: representative Western blots (left) and a summary of the densitometric analysis (right) are shown. n = 3 biological repeats (3 mice)/time point. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( E ) The amount of NT3 protein in the L3/4 spinal cord on different days as indicated after the first injection of paclitaxel. n = 3 biological repeated (3 mice)/time point. P > 0.05 by one-way ANOVA followed by post hoc Tukey test. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Injection, Produced, Western Blot

Data: mean ± SD. ( A , B ) Representative images of in situ hybridization histochemistry (ISHH) for Nt3 mRNA (red) and immunohistochemistry for β-tubulin III (green; A ) or glutamine synthetase (GS; green; B ) in the L3/4 DRGs 14 days after the first paclitaxel or vehicle injection. Cellular nuclei were labeled by 4’, 6-diamidino-2- phenylindole (DAPI; blue). n = 9–12 sections from three mice/group. * P < 0.05 by two-tailed unpaired Student t test. Scale bars: 50 µm. ( C ) Size distribution of Nt3 mRNA-labeled neuronal somata in the L3/4 DRGs 14 days after the first paclitaxel injection. Small, 25%, medium, 36%; large, 39%. ( D – H ) Representative images of ISHH for Nt3 mRNA (red) and immunohistochemistry for different DRG cell markers (calcitonin gene-related peptide (CGRP; green; D ), neurofilament 200 (NF200; green; E ), isolectin B4 (IB4; green; F ), or tyrosine hydroxylase (TH; green; G )) in the L3/4 DRGs 14 days after the first paclitaxel injection. Arrows: double-labeling neurons. Statistical summary of number of double-labeling neurons ( H ). n = 9–12 sections from three mice. Scale bar: 50 µm. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. ( A , B ) Representative images of in situ hybridization histochemistry (ISHH) for Nt3 mRNA (red) and immunohistochemistry for β-tubulin III (green; A ) or glutamine synthetase (GS; green; B ) in the L3/4 DRGs 14 days after the first paclitaxel or vehicle injection. Cellular nuclei were labeled by 4’, 6-diamidino-2- phenylindole (DAPI; blue). n = 9–12 sections from three mice/group. * P < 0.05 by two-tailed unpaired Student t test. Scale bars: 50 µm. ( C ) Size distribution of Nt3 mRNA-labeled neuronal somata in the L3/4 DRGs 14 days after the first paclitaxel injection. Small, 25%, medium, 36%; large, 39%. ( D – H ) Representative images of ISHH for Nt3 mRNA (red) and immunohistochemistry for different DRG cell markers (calcitonin gene-related peptide (CGRP; green; D ), neurofilament 200 (NF200; green; E ), isolectin B4 (IB4; green; F ), or tyrosine hydroxylase (TH; green; G )) in the L3/4 DRGs 14 days after the first paclitaxel injection. Arrows: double-labeling neurons. Statistical summary of number of double-labeling neurons ( H ). n = 9–12 sections from three mice. Scale bar: 50 µm. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: In Situ Hybridization, Immunohistochemistry, Injection, Labeling, Two Tailed Test

Data: mean ± SD. ( A ) Expression of NT3 protein in the ipsilateral L3/4 DRGs 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from the NT3 siRNA- or NC siRNA-microinjected male mice. n = 3 biological repeats (6 mice)/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( B – H ) Paw withdrawal frequency to 0.07 g ( B , F ) and 0.4 g ( C , G ) von Frey filament stimuli and paw withdrawal latency to heat ( D , H ) and cold ( E ) stimuli on the ipsilateral ( B – E ) and contralateral ( F – H ) side on days as indicated from male mice with DRG microinjection of NT3 siRNA or NC siRNA 7 days after the first injection of paclitaxel (PTX) or vehicle. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the paclitaxel plus NC siRNA-treated group at the corresponding time points by three-way ANOVA with repeated measures followed by post hoc Tukey test. ( I ) Levels of p-ERK1/2, total ERK1/2, and GFAP in the ipsilateral L3/4 dorsal horn 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from male mice with DRG microinjection of NT3 siRNA or NC siRNA. n = 3 mice/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by Tukey post hoc test. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. ( A ) Expression of NT3 protein in the ipsilateral L3/4 DRGs 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from the NT3 siRNA- or NC siRNA-microinjected male mice. n = 3 biological repeats (6 mice)/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( B – H ) Paw withdrawal frequency to 0.07 g ( B , F ) and 0.4 g ( C , G ) von Frey filament stimuli and paw withdrawal latency to heat ( D , H ) and cold ( E ) stimuli on the ipsilateral ( B – E ) and contralateral ( F – H ) side on days as indicated from male mice with DRG microinjection of NT3 siRNA or NC siRNA 7 days after the first injection of paclitaxel (PTX) or vehicle. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the paclitaxel plus NC siRNA-treated group at the corresponding time points by three-way ANOVA with repeated measures followed by post hoc Tukey test. ( I ) Levels of p-ERK1/2, total ERK1/2, and GFAP in the ipsilateral L3/4 dorsal horn 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from male mice with DRG microinjection of NT3 siRNA or NC siRNA. n = 3 mice/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by Tukey post hoc test. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Expressing, Injection, Microinjection

Data: mean ± SD. ( A ) Expression of NT3 protein in the ipsilateral L3/4 DRGs 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from the NT3 siRNA- or NC siRNA-microinjected female mice. n = 3 biological repeats (6 mice)/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( B – H ) Paw withdrawal frequency to 0.07 g ( B , F ) and 0.4 g ( C , G ) von Frey filament stimuli and paw withdrawal latency to heat ( D , H ) and cold ( E ) stimuli on the ipsilateral ( B – E ) and contralateral ( F – H ) side on the days as indicated from female mice with DRG microinjection of NT3 siRNA or NC siRNA on day 7 after the first injection of paclitaxel or vehicle. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the paclitaxel plus NC siRNA-treated group at the corresponding time points by three-way ANOVA with repeated measures followed by post hoc Tukey test. ( I ) Levels of p-ERK1/2, total ERK1/2, and GFAP in the ipsilateral L3/4 dorsal horn 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from female mice with DRG microinjection of NT3 siRNA or NC siRNA. n = 3 mice/group. ** P < 0.01 by two-way ANOVA followed by Tukey post hoc test. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. ( A ) Expression of NT3 protein in the ipsilateral L3/4 DRGs 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from the NT3 siRNA- or NC siRNA-microinjected female mice. n = 3 biological repeats (6 mice)/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( B – H ) Paw withdrawal frequency to 0.07 g ( B , F ) and 0.4 g ( C , G ) von Frey filament stimuli and paw withdrawal latency to heat ( D , H ) and cold ( E ) stimuli on the ipsilateral ( B – E ) and contralateral ( F – H ) side on the days as indicated from female mice with DRG microinjection of NT3 siRNA or NC siRNA on day 7 after the first injection of paclitaxel or vehicle. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the paclitaxel plus NC siRNA-treated group at the corresponding time points by three-way ANOVA with repeated measures followed by post hoc Tukey test. ( I ) Levels of p-ERK1/2, total ERK1/2, and GFAP in the ipsilateral L3/4 dorsal horn 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from female mice with DRG microinjection of NT3 siRNA or NC siRNA. n = 3 mice/group. ** P < 0.01 by two-way ANOVA followed by Tukey post hoc test. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Expressing, Injection, Microinjection

Data: mean ± SD. ( A , B ) Levels of Nt3 mRNA ( A ) and NT3 protein ( B ) in the L3/4 DRGs 28 days after the first intraperitoneal (i.p.) injection of paclitaxel (PTX) or vehicle (Veh) from the tamoxifen-treated NT3 f/f mice and NT3 cKD mice. n = 3 biological repeated (3 mice)/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( C – I ) Paw withdrawal frequency to 0.07 g ( C , G ) and 0.4 g ( D , H ) von Frey filament stimuli and paw withdrawal latency to heat ( E , I ) and cold ( F ) stimuli on the left ( C – F ) and right ( G – I ) side on days as indicated from NT3 f/f mice and NT3 cKD with i.p. injection of tamoxifen (Tam) daily for 7 consecutive days starting at day 7 after the first i.p. injection of paclitaxel (PTX) or vehicle. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the paclitaxel-treated NT3 f/f mice at the corresponding days by three-way ANOVA with repeated measures followed by post hoc Tukey test. ( J , K ) Spontaneous ongoing pain as assessed by the CPP test 21 days after the first i.p. injection of paclitaxel (PTX) or vehicle in the tamoxifen-treated NT3 f/f mice and NT3 cKD mice. Time spent in each chamber ( J ) and difference scores for chamber preferences calculated by subtracting preconditioning (Pre) preference time from postconditioning (Post) time spent in the lidocaine-paired chamber ( K ). n = 9 mice/group. ** P < 0.01 by three-way ANOVA with repeated measures followed by post hoc Tukey test ( J ) or by two-way ANOVA followed by Tukey post hoc test ( K ). ( L ) Levels of p-ERK1/2, total ERK1/2 and GFAP in the L3/4 dorsal horn 28 days after the first i.p. injection of paclitaxel (PTX) or vehicle in the tamoxifen-treated NT3 f/f mice and NT3 cKD mice. n = 3 mice/group. * P < 0.05, ** P < 0 . 01 by two-way ANOVA followed by post hoc Tukey test. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. ( A , B ) Levels of Nt3 mRNA ( A ) and NT3 protein ( B ) in the L3/4 DRGs 28 days after the first intraperitoneal (i.p.) injection of paclitaxel (PTX) or vehicle (Veh) from the tamoxifen-treated NT3 f/f mice and NT3 cKD mice. n = 3 biological repeated (3 mice)/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( C – I ) Paw withdrawal frequency to 0.07 g ( C , G ) and 0.4 g ( D , H ) von Frey filament stimuli and paw withdrawal latency to heat ( E , I ) and cold ( F ) stimuli on the left ( C – F ) and right ( G – I ) side on days as indicated from NT3 f/f mice and NT3 cKD with i.p. injection of tamoxifen (Tam) daily for 7 consecutive days starting at day 7 after the first i.p. injection of paclitaxel (PTX) or vehicle. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the paclitaxel-treated NT3 f/f mice at the corresponding days by three-way ANOVA with repeated measures followed by post hoc Tukey test. ( J , K ) Spontaneous ongoing pain as assessed by the CPP test 21 days after the first i.p. injection of paclitaxel (PTX) or vehicle in the tamoxifen-treated NT3 f/f mice and NT3 cKD mice. Time spent in each chamber ( J ) and difference scores for chamber preferences calculated by subtracting preconditioning (Pre) preference time from postconditioning (Post) time spent in the lidocaine-paired chamber ( K ). n = 9 mice/group. ** P < 0.01 by three-way ANOVA with repeated measures followed by post hoc Tukey test ( J ) or by two-way ANOVA followed by Tukey post hoc test ( K ). ( L ) Levels of p-ERK1/2, total ERK1/2 and GFAP in the L3/4 dorsal horn 28 days after the first i.p. injection of paclitaxel (PTX) or vehicle in the tamoxifen-treated NT3 f/f mice and NT3 cKD mice. n = 3 mice/group. * P < 0.05, ** P < 0 . 01 by two-way ANOVA followed by post hoc Tukey test. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Injection

Data: mean ± SD. ( A , B ) Levels of Nt3 mRNA ( A ) and NT3 protein ( B ) in the ipsilateral L3/4 DRGs 8 weeks after microinjection of AAV5-NT3 or control AAV5-GFP in male mice. n = 3 biological repeats (6 mice)/group. ** P < 0.01 by two-tailed unpaired Student t test. ( C – F ) Paw withdrawal frequency to 0.07 g ( C ) and 0.4 g ( D ) von Frey filament stimuli and paw withdrawal latency to heat ( E ) and cold ( F ) stimuli on the ipsilateral and contralateral sides on weeks as indicated after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the AAV5-GFP group on the ipsilateral side at the corresponding time points by three-way ANOVA with repeated measures followed by Tukey post hoc test. ( G , H ) Spontaneous ongoing pain as assessed by the CPP test 8 weeks after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. Time spent in each chamber ( G ) and difference scores for chamber preferences calculated by subtracting preconditioning (Pre) preference time from postconditioning (Post) time spent in the lidocaine-paired chamber ( H ). n = 9 mice/group. ** P < 0.01 by two-way ANOVA with repeated measures followed by post hoc Tukey test ( G ) or by two-tailed unpaired Student t test ( H ). ( I ) Levels of p-ERK1/2, total ERK1/2 and GFAP in the ipsilateral L3/4 dorsal horn 8 weeks after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. n = 3 mice/group. ** P < 0.01 by two-tailed unpaired Student t test. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. ( A , B ) Levels of Nt3 mRNA ( A ) and NT3 protein ( B ) in the ipsilateral L3/4 DRGs 8 weeks after microinjection of AAV5-NT3 or control AAV5-GFP in male mice. n = 3 biological repeats (6 mice)/group. ** P < 0.01 by two-tailed unpaired Student t test. ( C – F ) Paw withdrawal frequency to 0.07 g ( C ) and 0.4 g ( D ) von Frey filament stimuli and paw withdrawal latency to heat ( E ) and cold ( F ) stimuli on the ipsilateral and contralateral sides on weeks as indicated after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the AAV5-GFP group on the ipsilateral side at the corresponding time points by three-way ANOVA with repeated measures followed by Tukey post hoc test. ( G , H ) Spontaneous ongoing pain as assessed by the CPP test 8 weeks after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. Time spent in each chamber ( G ) and difference scores for chamber preferences calculated by subtracting preconditioning (Pre) preference time from postconditioning (Post) time spent in the lidocaine-paired chamber ( H ). n = 9 mice/group. ** P < 0.01 by two-way ANOVA with repeated measures followed by post hoc Tukey test ( G ) or by two-tailed unpaired Student t test ( H ). ( I ) Levels of p-ERK1/2, total ERK1/2 and GFAP in the ipsilateral L3/4 dorsal horn 8 weeks after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. n = 3 mice/group. ** P < 0.01 by two-tailed unpaired Student t test. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Microinjection, Control, Two Tailed Test

Data: mean ± SD. ( A , B ) Levels of Nt3 mRNA ( A ) and NT3 protein ( B ) in the ipsilateral L3/4 DRGs 8 weeks after microinjection of AAV5-NT3 or control AAV5-GFP in female mice. n = 3 biological repeats (6 mice)/group. ** P < 0.01 by two-tailed unpaired Student t test. ( C – F ) Paw withdrawal frequency to 0.07 g ( C ) and 0.4 g ( D ) von Frey filament stimuli and paw withdrawal latency to heat ( E ) and cold ( F ) stimuli on the ipsilateral and contralateral sides on weeks as indicated after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the AAV5-GFP group on the ipsilateral side at the corresponding time points by three-way ANOVA with repeated measures followed by the Tukey post hoc test. ( G , H ) Spontaneous ongoing pain as assessed by the CPP test 8 weeks after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. Time spent in each chamber ( G ) and difference scores for chamber preferences calculated by subtracting preconditioning (Pre) preference time from postconditioning (Post) time spent in the lidocaine-paired chamber ( H ). n = 9 mice/group. ** P < 0.01 by two-way ANOVA with repeated measures followed by post hoc Tukey test ( G ) or by two-tailed unpaired Student t test ( H ). ( I ) Levels of p-ERK1/2, total ERK1/2 and GFAP in the ipsilateral L3/4 dorsal horn 8 weeks after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. n = 3 mice/group. ** P < 0.01 by two-tailed unpaired Student t test. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. ( A , B ) Levels of Nt3 mRNA ( A ) and NT3 protein ( B ) in the ipsilateral L3/4 DRGs 8 weeks after microinjection of AAV5-NT3 or control AAV5-GFP in female mice. n = 3 biological repeats (6 mice)/group. ** P < 0.01 by two-tailed unpaired Student t test. ( C – F ) Paw withdrawal frequency to 0.07 g ( C ) and 0.4 g ( D ) von Frey filament stimuli and paw withdrawal latency to heat ( E ) and cold ( F ) stimuli on the ipsilateral and contralateral sides on weeks as indicated after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the AAV5-GFP group on the ipsilateral side at the corresponding time points by three-way ANOVA with repeated measures followed by the Tukey post hoc test. ( G , H ) Spontaneous ongoing pain as assessed by the CPP test 8 weeks after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. Time spent in each chamber ( G ) and difference scores for chamber preferences calculated by subtracting preconditioning (Pre) preference time from postconditioning (Post) time spent in the lidocaine-paired chamber ( H ). n = 9 mice/group. ** P < 0.01 by two-way ANOVA with repeated measures followed by post hoc Tukey test ( G ) or by two-tailed unpaired Student t test ( H ). ( I ) Levels of p-ERK1/2, total ERK1/2 and GFAP in the ipsilateral L3/4 dorsal horn 8 weeks after microinjection of AAV5-NT3 or AAV5-GFP into unilateral L3/4 DRGs. n = 3 mice/group. ** P < 0.01 by two-tailed unpaired Student t test. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Microinjection, Control, Two Tailed Test

Data: mean ± SD. ( A , B ) Levels of Nt3 , TrkC , and p75 NTR mRNAs ( A ) and their respective proteins ( B ) in the ipsilateral L3/4 DRGs 42 days after microinjection of AAV5-NT3 (NT3) or AAV5-GFP (GFP) into unilateral L3/4 DRGs of the mice with co-microinjection of control scrambled siRNA (Scr-si), TrkC siRNA (TrkC-si), or p75 NTR siRNA (p75-si). n = 3 biological repeats (6 mice)/group. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by post hoc Tukey test. ( C – I ) Paw withdrawal frequencies to 0.07 g ( C , G ) and 0.4 g ( D , H ) von Frey filament stimuli and paw withdrawal latencies to heat ( E, I ) and cold stimuli ( F ) on the ipsilateral ( C – F ) and contralateral ( G – I ) sides on days as indicated after AAV-NT3 or AAV-GFP microinjection in the mice with co-microinjection of control scrambled siRNA (Scr-si), TrkC siRNA (TrkC-si), or p75 NTR siRNA (p75-si) starting at 35 days after AAV5 microinjection. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the AAV5-NT3 plus control scrambled siRNA-treated group at the corresponding days by two-way ANOVA with repeated measures followed by Tukey post hoc test. ( J ) Levels of p-ERK1/2, total ERK1/2 and GFAP in the ipsilateral L3/4 dorsal horn on day 42 after microinjection of AAV5-NT3 (NT3) or AAV5-GFP (GFP) into unilateral L3/4 DRGs of the mice with co-microinjection of control scrambled siRNA (Scr-si), TrkC siRNA (TrkC-si), or p75 NTR siRNA (p75-si). n = 3 mice/group. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by Tukey post hoc test. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. ( A , B ) Levels of Nt3 , TrkC , and p75 NTR mRNAs ( A ) and their respective proteins ( B ) in the ipsilateral L3/4 DRGs 42 days after microinjection of AAV5-NT3 (NT3) or AAV5-GFP (GFP) into unilateral L3/4 DRGs of the mice with co-microinjection of control scrambled siRNA (Scr-si), TrkC siRNA (TrkC-si), or p75 NTR siRNA (p75-si). n = 3 biological repeats (6 mice)/group. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by post hoc Tukey test. ( C – I ) Paw withdrawal frequencies to 0.07 g ( C , G ) and 0.4 g ( D , H ) von Frey filament stimuli and paw withdrawal latencies to heat ( E, I ) and cold stimuli ( F ) on the ipsilateral ( C – F ) and contralateral ( G – I ) sides on days as indicated after AAV-NT3 or AAV-GFP microinjection in the mice with co-microinjection of control scrambled siRNA (Scr-si), TrkC siRNA (TrkC-si), or p75 NTR siRNA (p75-si) starting at 35 days after AAV5 microinjection. n = 9 mice/group. * P < 0.05, ** P < 0.01 versus the AAV5-NT3 plus control scrambled siRNA-treated group at the corresponding days by two-way ANOVA with repeated measures followed by Tukey post hoc test. ( J ) Levels of p-ERK1/2, total ERK1/2 and GFAP in the ipsilateral L3/4 dorsal horn on day 42 after microinjection of AAV5-NT3 (NT3) or AAV5-GFP (GFP) into unilateral L3/4 DRGs of the mice with co-microinjection of control scrambled siRNA (Scr-si), TrkC siRNA (TrkC-si), or p75 NTR siRNA (p75-si). n = 3 mice/group. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by Tukey post hoc test. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Microinjection, Control

Data: mean ± SD. Data: mean ± SD. ( A – C ) Levels of CCL2 and TrkC proteins in the ipsilateral L3/4 DRGs 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from the NT3 siRNA- or negative control scrambled siRNA (NC siRNA)-microinjected male ( A ) and female ( B ) mice or 28 days after the first injection of paclitaxel or vehicle from the tamoxifen-treated NT3 f/f mice and NT3 cKD mice ( C ). n = 3 biological repeats (6 mice in A and B and 3 mice in C)/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( D ) Level of CCL2 protein in the ipsilateral L3/4 DRGs 42 days after microinjection of AAV5-NT3 (NT3) or AAV5-GFP (GFP) into unilateral L3/4 DRGs of the mice with co-microinjection of control scrambled siRNA (Scr-si), or TrkC siRNA (TrkC-si). n = 3 biological repeats (6 mice)/group. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by post hoc Tukey test. ( E – H ) Levels of Nt3 mRNA ( E , G ), Ccl2 mRNA ( E , G ) and their respective proteins ( F , H ) in the cultured DRG neurons (E-F) or in human neuroblastoma cell lines ( G , H ) with transfection of NT3 siRNA or negative control scrambled siRNA (NC siRNA) plus with exposure to paclitaxel (PTX) or vehicle (Veh). n = 3 biological repeats. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by post hoc Tukey test. ( I , J ) Levels of Nt3 mRNA ( I ), Ccl2 mRNA ( I ) and their respective proteins ( J ) in the cultured DRG neurons with transduction of AAV5-NT3 (NT3) or AAV5-GFP (GFP) plus with transfection of NT3 siRNA or negative control scrambled siRNA (NC siRNA). n = 3 biological repeats. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by post hoc Tukey test. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Data: mean ± SD. Data: mean ± SD. ( A – C ) Levels of CCL2 and TrkC proteins in the ipsilateral L3/4 DRGs 14 days after the first injection of paclitaxel (PTX) or vehicle (Veh) from the NT3 siRNA- or negative control scrambled siRNA (NC siRNA)-microinjected male ( A ) and female ( B ) mice or 28 days after the first injection of paclitaxel or vehicle from the tamoxifen-treated NT3 f/f mice and NT3 cKD mice ( C ). n = 3 biological repeats (6 mice in A and B and 3 mice in C)/group. * P < 0.05, ** P < 0.01 by two-way ANOVA followed by post hoc Tukey test. ( D ) Level of CCL2 protein in the ipsilateral L3/4 DRGs 42 days after microinjection of AAV5-NT3 (NT3) or AAV5-GFP (GFP) into unilateral L3/4 DRGs of the mice with co-microinjection of control scrambled siRNA (Scr-si), or TrkC siRNA (TrkC-si). n = 3 biological repeats (6 mice)/group. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by post hoc Tukey test. ( E – H ) Levels of Nt3 mRNA ( E , G ), Ccl2 mRNA ( E , G ) and their respective proteins ( F , H ) in the cultured DRG neurons (E-F) or in human neuroblastoma cell lines ( G , H ) with transfection of NT3 siRNA or negative control scrambled siRNA (NC siRNA) plus with exposure to paclitaxel (PTX) or vehicle (Veh). n = 3 biological repeats. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by post hoc Tukey test. ( I , J ) Levels of Nt3 mRNA ( I ), Ccl2 mRNA ( I ) and their respective proteins ( J ) in the cultured DRG neurons with transduction of AAV5-NT3 (NT3) or AAV5-GFP (GFP) plus with transfection of NT3 siRNA or negative control scrambled siRNA (NC siRNA). n = 3 biological repeats. * P < 0.05, ** P < 0.01 by one-way ANOVA followed by post hoc Tukey test. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Injection, Negative Control, Microinjection, Control, Cell Culture, Transfection, Transduction

Co-expression analysis of Nt3 mRNA, TrkC mRNA and Ccl2 mRNA in individual large (>35 μm in diameter; A ), medium (25–35 µm in diameter; B ), and small (<25 μm in diameter; C ) DRG neurons from naive mice ( n = 2) by single-cell RT-PCR assay. NeuN mRNA is used as a neuronal marker. Tuba-1α mRNA is used as a loading control. M DNA ladder marker, NC no cDNA. n = 5 neurons/size. .

Journal: EMBO Reports

Article Title: NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons

doi: 10.1038/s44319-024-00133-6

Figure Lengend Snippet: Co-expression analysis of Nt3 mRNA, TrkC mRNA and Ccl2 mRNA in individual large (>35 μm in diameter; A ), medium (25–35 µm in diameter; B ), and small (<25 μm in diameter; C ) DRG neurons from naive mice ( n = 2) by single-cell RT-PCR assay. NeuN mRNA is used as a neuronal marker. Tuba-1α mRNA is used as a loading control. M DNA ladder marker, NC no cDNA. n = 5 neurons/size. .

Article Snippet: The primary antibodies included rabbit anti-NT3 (1:250; Alomone Labs, catalog number: ANT-003; Jerusalem, Isreael), rabbit anti-MCP-1 (1:1000, catalog number: ab315478; Abcam; Waltham, MA), rabbit anti-p75NTR (1:1000, catalog number: 07-476; Sigma-Aldrich), rabbit anti-TrkC (1:400, catalog number: ANT-020; Alomone), rabbit anti-ERK1/2 (1:1000, catalog number: 4370S; Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (p-ERK1/2; 1:1000; catalog number: 3670S; Cell Signaling Technology), mouse anti-GFAP (1:1000, catalog number: 3670S; Cell Signaling Technology), rabbit anti-GAPDH (1:1000, catalog number: G9545; Sigma-Aldrich) and mouse anti-actin (1:1000, catalog number: sc-47778; Santa Cruz).

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Marker, Control